Abstract: A method for determining whether bacteria in a sample obtained from a subject at a point of care in a clinical setting is susceptible to an antibiotic, within a time period associated with a point of care. The method includes measuring a bioluminescent indication from a first test sample based on released ATP to determine a characteristic associated with the bioluminescent indication and comparing the characteristic associated with the bioluminescent indication to a first threshold. The method includes determining whether a bacteria is present by comparing the difference between a characteristic associated with a first confirmatory bioluminescent signal and a characteristic associated with a second confirmatory bioluminescent signal to an confirmatory threshold.

Abstract: A method for determining whether bacteria in a sample obtained from a subject at a point of care in a clinical setting is susceptible to an antibiotic, within a time period associated with a point of care. The method includes measuring a bioluminescent indication from a first test sample based on released ATP to determine a characteristic associated with the bioluminescent indication and comparing the characteristic associated with the bioluminescent indication to a first threshold. The method includes determining whether a bacteria is present by comparing the difference between a characteristic associated with a first confirmatory bioluminescent signal and a characteristic associated with a second confirmatory bioluminescent signal to an confirmatory threshold.

Abstract: A method includes obtaining a sample from a patient; applying, to the sample, a reagent to cause bacterial cells to release adenosine triphosphate (ATP) when the sample includes the bacterial cells; applying another reagent that reacts with the ATP to form a colorimetric agent; detecting whether the sample changes in appearance as observed by an unaided eye of a practitioner when a concentration of the agent is greater than a threshold; identifying a time period from when the other reagent is applied to when the change in appearance is detected; and determines a severity, of a bacterial infection, based on the time period. The severity corresponds to a severity level when the time period is less than a duration of a point of care visit by a first amount, or a higher severity level when the time period is less than the duration by more than the first amount.

Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions.

Abstract: A hand sanding block accepts the continuous sanding belts that are normally used on electrically powered belt sanders. Shoulder stops and biasing springs within the device allow for two positions of the block and keep the movable tensioning arm from coming apart from the block. One position, the withdrawn position, allows for easy removal, replacement, or adjustment of the continuous sanding belt. A second, or extended position, tensions the sanding belt to keep it in place on the sanding block.

Abstract: The present invention provides a compound of formula I 1

Abstract: Various embodiments of the invention include a financial transactions processing system to process financial transactions for a customer in a financial institution. One embodiment includes an entrance, a concierge desk, two or more teller towers, and a teller cash dispenser. The teller towers may contain a teller computer, a top surface, one or more cash slots, and a cash box. A bank employee at the teller tower performs transactions for a customer, such as depositing cash, performing account inquiries, etc. In one embodiment, the teller cash dispenser receives information regarding a withdrawal transaction and dispenses cash to a customer or the customer receives a printed receipt to receive cash from the cash dispenser. In another embodiment, the teller towers are arranged in a circle, semicircle, elongated circle, or oval.

Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

Abstract: The present invention provides a compound of formula I 1

Abstract: The present invention provides a compound of formula I These compounds are useful as antiviral agents, in particular, as agents against viruses of the herpes family.

Abstract: The present invention provides a compound of formula I Wherein R1 is C1-7 alkyl, optionally substituted by hydroxy or NR4R5; R2 is C1-7 alkyl substituted by hydroxy or NR4R5; R3 is H, F or C1-7 alkoxy; R4 and R5 together with N are a 5- or 6-membered heterocyclic moiety having 1-3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur in which sulfur may be substituted by one (1) or two (2) oxygen atoms; and pharmaceutically acceptable salts thereof Compounds of formula I of the present invention are useful as antiviral agents.

Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

Abstract: The present invention relates to compounds of formula I and II which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus.

Abstract: The present invention presents novel 1,3,4-thiadiazole derivatives of formula I ##STR1## which have useful antiviral activity against herpes virus, cytomegalovirus (CMV).

Abstract: The present invention provides 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula I ##STR1## These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.

Abstract: The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl?b!pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R.sub.10 and R.sub.20 taken together are formulae (III) and (IV).

Abstract: The present invention relates to compounds of formula I which are 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl?b!pyran-2-ones useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus. ##STR1## Wherein R.sub.10 and R.sub.

Abstract: In a video signal distribution system in which a plurality of video signals are modulated onto individual carrier signals spaced over a band of frequencies to form a composite signal for transmission over cables of the system, a point-to-point radio link forming part of the distribution system is provided in which the composite signal is transmitted as double side band phase modulation of a single microwave carrier signal.

Abstract: In a video signal distribution system in which a plurality of video signals are modulated onto individual carrier signals spaced over a band of frequencies to form a composite signal for transmission over cables of the system, a point-to-point radio link forming part of the distribution system is provided in which the composite signal is transmitted as double side band amplitude modulation of a single microwave carrier signal.